KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Interest & Investment Income (2023 - 2025)

Nektar Therapeutics has reported Interest & Investment Income over the past 8 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $2.8 million for Q4 2025, down 5.64% from a year ago — trailing twelve months through Dec 2025 was $10.4 million (down 28.01% YoY), and the annual figure for FY2025 was $10.4 million, down 28.01%.
  • Interest & Investment Income for Q4 2025 was $2.8 million at Nektar Therapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for NKTR hit a ceiling of $5.2 million in Q3 2023 and a floor of $2.0 million in Q2 2025.
  • Median Interest & Investment Income over the past 3 years was $3.7 million (2024), compared with a mean of $3.7 million.
  • Biggest five-year swings in Interest & Investment Income: decreased 2.65% in 2024 and later crashed 49.53% in 2025.
  • Nektar Therapeutics' Interest & Investment Income stood at $4.6 million in 2023, then tumbled by 36.28% to $2.9 million in 2024, then decreased by 5.64% to $2.8 million in 2025.
  • The last three reported values for Interest & Investment Income were $2.8 million (Q4 2025), $2.8 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.